Patents Examined by Gary Kunz
  • Cosmetic formulations of having high aqueous solubility and low flash points
    Patent number: 6881399
    Abstract: The invention provides compositions comprising a) at least one quaternary ammonium compound, and b) at least one polyhydric alcohol having 5 to 12 carbon atoms. The compositions have low setting points, good solubility and dispersibility in aqueous media and a low flash point.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: April 19, 2005
    Assignee: Clariant GmbH
    Inventors: Robert Milbradt, Sonja Klein, Franz Xaver Scherl, Erich Gatter, Adelgunde Oberhauser
  • Human ?-7 nicotinic receptor promoter
    Patent number: 6875606
    Abstract: The present invention is directed to methods and compositions related to ?7 acetylcholine nicotinic receptor genes, in particular, the human ?7 nicotinic acetylcholine receptor gene. This ?7 acetylcholine nicotinic receptor gene is associated with the pathophysiological aspects of the disease schizophrenia. The present invention further provides methods and compositions to screen populations for abnormal ?7, as well as methods and compositions for development of therapeutics.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: April 5, 2005
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventors: Sherry Leonard, Robert Freedman
  • Methods of treatment of Alzheimer's disease
    Patent number: 6875434
    Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disesase, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: April 5, 2005
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • ASP2
    Patent number: 6870030
    Abstract: ASP2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ASP2 polypeptides and polynucleotides in the design of protocols for the treatment of Alzheimer's Disease, cancer, and prohormone processing, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: March 22, 2005
    Assignees: Smithkline Beecham Corporation, Smithkline Beecham plc
    Inventors: David J. Powell, Conrad G. Chapman, Kay Murphy, Trudi S. Smith
  • Methods of inducing hair growth and coloration
    Patent number: 6867179
    Abstract: Methods to control, or manipulate, melanocyte and keratinocyte cell death are disclosed. In particular, a method of preventing epidermal melanocyte cell loss due to injury in a vertebrate is disclosed. Also disclosed is a method of inducing hair growth in a vertebrate, a method of inducing hair color in a vertebrate, a method of inducing skin color in a vertebrate, a method of treating baldness in an individual, and a method of treating alopecia areata in an individual.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: March 15, 2005
    Assignee: Trustees of Boston University
    Inventors: Barbara A. Gilchrest, Mina Yaar, Mark Eller
  • Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
    Patent number: 6866839
    Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: March 15, 2005
    Assignee: Sepracor Inc.
    Inventors: Gunnar Aberg, John Morley
  • Sustained release ranolazine formulations
    Patent number: 6864258
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: July 7, 2003
    Date of Patent: March 8, 2005
    Inventor: Andrew A. Wolff
  • Polynucleotides and proteins encoded thereby
    Patent number: 6863889
    Abstract: The present invention provides novel isolated SECX polynucleotides and the membrane-associated or selected polypeptides encoded by the SECX polynucleotides. Also provided are the antibodies that immunospecifically bind to a SECX polypeptide or any derivative, variant, mutant or fragment of the SECX polypeptide, polynucleotide or antibody. The invention additionally provide methods in which the SECX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: March 8, 2005
    Assignee: CuraGen Corporation
    Inventors: Richard A. Shimkets, William J. LaRochelle
  • Purified antigen for Alzheimer's disease and methods of obtaining and using same
    Patent number: 6864062
    Abstract: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: March 8, 2005
    Assignee: Molecular Geriatrics Corporation
    Inventors: Raymond P. Zinkowski, Daniel J. Kerkman, Russell E. Kohnken, John F. DeBernardis, Peter Davies
  • Dysfunctional satiety center syndrome and method of treatment therefor
    Patent number: 6861073
    Abstract: The present invention provides a method of treating obesity in mammals, particularly humans. The method comprises the step of administering a dietary supplement that includes about 25 mg to about 10 g calcium carbonate precipitate; about 25 mg to about 10 g coral calcium; about 10 mg to about 10 g magnesium carbonate; about 10 mg to about 5 g potassium carbonate; a plurality of vitamins, including Vitamin C; and a plurality of amino acids.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: March 1, 2005
    Inventor: Paul Ling Tai
  • Use of nanoscalar water-soluble ?-(1,3) glucans
    Patent number: 6858214
    Abstract: The invention relates to the use of nanoscalar water-soluble ?-(1,3) glucans, which are essentially free from ?-(1,6) links and have particle diameters ranging from 10 to 300 nm for producing cosmetic and/or pharmaceutical preparations. When applied topically, the especially fine dispersion of the particles, compared to prior art glucans, facilitates their rapid penetration of both the stratum corneum of the skin and the keratin fibres of the hair.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: February 22, 2005
    Assignee: Biotec ASA
    Inventors: Christian Kropf, Ute Griesbach, Bernd Fabry, Rolf E. Engstad
  • Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
    Patent number: 6855727
    Abstract: An antifatigue composition for reducing muscular fatigue or the like during or after exercise, which includes an imidazole compound obtained from extracts of fishes, shelifishes, fowl, flesh or the like, as an active ingredient. The imidazole compound in the antifatigue composition is preferably at least one compound selected from the group consisting of histidine, anserine, carnosine, valenine and salts thereof. The antifatigue composition preferably further contains D-ribose as an active ingredient. By orally ingesting the antifatigue composition, the amount of lactic acid in plasma during or after exercise can be kept low, and therefore muscle fatigue caused by exercise can be controlled, and as a result, the ability to exercise can be improved.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: February 15, 2005
    Assignee: Yaizu Suisankagaku Industry Co., Ltd.
    Inventors: Yoshiharu Matahira, Kazuaki Kikuchi
  • Macrophage-infecting parasites expressing a granulocyte macrophage colony stimulated factor
    Patent number: 6855537
    Abstract: Strains of Leishmania and other macrophage-infecting parasites are provided which express the GM-CSF gene which are useful in treating hosts infected by the parasite and in protecting hosts against disease caused by infection of hosts by parasites. The parasites are reduced in their ability to infect or survive in macrophages and hence are attenuated. At least one gene of the parasite contributing to the virulence thereto may be functionally disabled. The attenuated strains may be used for administration to a host (a) to treat a host infected by Leishmania or (b) to confer protection against disease caused by a virulent Leishmania strain, or as a diagnostic reagent.
    Type: Grant
    Filed: September 16, 1997
    Date of Patent: February 15, 2005
    Assignee: Aventis Pasteur Limited
    Inventors: Barbara Papadopoulu, Marc Ouellette, Martin Olivier
  • Heterodimeric opioid G-protein coupled receptors
    Patent number: 6855807
    Abstract: Opioid receptors form functional heterodimers with each other and with other G-protein coupled receptors, such as dopamine receptors, adrenergic receptors, or chemokine receptors. These receptors can be exploited for high throughput screening of compounds to identify heterodimer opioid receptor modulators (agonists and antagonists). The invention also relates to identification of novel heterodimer receptor ligands and synergistic compositions, which can provide strategies for analgesia, narcotic addiction, hypertension, HIV infection, and immune system function.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: February 15, 2005
    Assignee: New York University
    Inventors: Lakshmi Arehole Devi, Bryen Alexander Jordan
  • Absorption promoting agent
    Patent number: 6855332
    Abstract: The present invention relates to pharmaceutical compositions comprising polyoxyethylene glycol, fatty acid mono- and diglyceride ester as an absorption promoting agent and an absorption controlling agent together with a therapeutically, prophylactically and/or diagnostically active substance. The pharmaceutical compositions are especially suitable for mucosal administration such as intranasal administration.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: February 15, 2005
    Assignee: Lyfjathroun hf.
    Inventors: Sveinbjorn Gizurarson, Sigridur Olafsdottir, Jakob Lindal Kristinsson, Kolbrun Hrafnkelsdottir, David Rurik Olafsson, Oddur Ingolfsson, Ellen Ruth Ingimundardottir
  • Methods and compositions for treating ocular disorders
    Patent number: 6855690
    Abstract: The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: February 15, 2005
    Assignee: Children's Medical Center Corporation
    Inventor: Larry I. Benowitz
  • Method of identifying compounds that modulate human histamine H3 receptor
    Patent number: 6855560
    Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: February 15, 2005
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Timothy W. Lovenberg, Mark Erlander, Arne Huvar, Jayashree Pyati
  • Ketamine treatment of restless legs syndrome
    Patent number: 6855735
    Abstract: The present invention is directed to a method for treating symptoms associated with Restless Legs Syndrome (RLS). The method includes administering to a warm-blooded animal in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with RLS.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: February 15, 2005
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventor: Robert Friedman
  • Methods of screening for agents that promote nerve cell growth
    Patent number: 6852496
    Abstract: Analogs of FK506 that do not bind FKBP-12 have been found to effectively promote nerve cell growth and regeneration, thereby speeding functional recovery of damaged nervous tissue and axonal regeneration without causing immunosuppression.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: February 8, 2005
    Assignee: Oregon Health and Science University
    Inventor: Bruce G. Gold
  • Tyrosine kinase receptors and ligands
    Patent number: 6852838
    Abstract: The present invention provides for a gene, designated as musk, that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides for an isolated polypeptide which activates MuSK receptor. The invention further provides for a polypeptide which is functionally equivalent to the MuSK activating polypeptide. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the musk gene product. The present invention also provides for diagnostic and therapeutic methods based on molecules that activate MuSK.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: February 8, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, David J. Glass, David C. Bowen, George D. Yancopoulos